Samsung is backing Alzheimer’s disease blood test developer C2N Diagnostics, with $10 million to help scale up its commercial work and R&D pipeline. The conglomerate’s investment—which collectively ...
ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, today announced a $10 million USD investment from Samsung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback